INFU (76) OSUR (32) TMCI (41) CLPT (34) ⌘ Pro Terminal →

Anika Therapeutics Inc. (ANIK) — RQD Stock Rating Cockpit

$21.79 +1.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.79

Anika Therapeutics Inc. (ANIK) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $291.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $21.79 (+0.01%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 3.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-1.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANIK)Realized 20D OHLCV Swing Band: ±8.2%

Deterministic 5-Pillar Attribution (55/100 Composite)

🔍 WHY ANIK SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (24% of score)

FRED Regime × Technicals: 92% of 52W Range • RSI-14 at 53.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 3.9% FCF Margin ($4.4M FCF) & 56.6% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)

Dilution Drag (+1.36% YoY Shares) & executive Form 4 sales trim 13 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$19.58+2% Next Q

Q2 (-2Q)

Grade C-$19.98+7.2% Next Q

Q3 (-1Q)

Grade C-$21.42+1.7% Next Q

Current

Grade D+$21.79-0.5% Hist 90D α

Trajectory: D (47) → D+ (55)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ANIK Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, ANIK faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($20.66) or 200D SMA ($16.07) invalidates the momentum regime and cuts Target Base ($21.50) toward Bear Floor ($16.77).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANIK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ANIK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 55%NO 45%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

53.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE92% OF RANGE

L: $9$21.79H: $23

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (57% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on ANIK

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

-10.2% ROIC with 56.6% gross margin and 1.50% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 4.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (53)

19/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like ANIK

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANIK)

✓Walkthrough of ANIK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ANIK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +75.02%▲ ASCENDING CHANNEL

2026-10-30O $21.80H $21.80L $20.81C $21.79VOL 66.7K

RES: $27.27SUP: $19.26SMA50: $20.66SMA200: $16.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANIK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANIK Butterfly Map → + Track ANIK →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANIK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANIK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ANIK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANIK)

Health Care Rank #281 of 1016 ⚔️ INFU vs ANIK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANIK vs. INFU, OSUR, TMCI, CLPT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Anika Therapeutics Inc. (ANIK) ranks #281 by composite RQD confidence (55/100, grade D+) and #522 by equity capitalization ($291.6M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while INFU leads on capital efficiency and profitability with 12.8% ROIC and 56.0% gross margin. INFU currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with ANIK at 55/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ANIK ACTIVE Anika Therapeutics Inc.	D+	55/100	—	56.6%	-10.2%	+1.11%	$291.6M	Benchmark Subject
INFU InfuSystems Holdings Inc.	B+	76/100	43.4x	56.0%	12.8%	+0.91%	$287.8M	/infu-vs-anik →
OSUR OraSure Technologies Inc.	E	32/100	—	41.9%	-35.0%	-0.49%	$281.4M	/osur-vs-anik →
TMCI Treace Medical Concepts Inc.	D-	41/100	—	79.8%	-32.4%	+4.76%	$329.1M	/tmci-vs-anik →
CLPT ClearPoint Neuro Inc.	E	34/100	—	61.4%	-35.0%	+1.23%	$342.7M	/clpt-vs-anik →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000898437

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anika Therapeutics Inc. (ANIK) reported GAAP revenue of $112.8M (-5.9% vs. FY2024 revenue of $119.9M , and -6.6% cumulative change since FY2023) , GAAP net income of -$11.0M, operating cash flow of $11.2M, and free cash flow of $4.4M (+287.1% YoY). On the balance sheet, ANIK closed FY2025 with $190.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$112.8M	-$11.0M	$11.2M	$4.4M	$190.3M	—
FY2024 (FY)	2024-12-31	$119.9M	-$56.0M	$5.4M	-$2.3M	$202.7M	—
FY2023 (FY)	2023-12-31	$120.8M	-$83.0M	-$1.8M	-$1.8M	—	—

3. ANIK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANIK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Anika Therapeutics Inc. (NASDAQ: ANIK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $21.79 (+1.11% 1D, market cap $291.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ANIK ranks #281 in composite RQD confidence.

How does ANIK compare to INFU and OSUR in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ANIK carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -10.2%. By comparison, INFU (InfuSystems Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 43.4x, ROIC 12.8%, cap $287.8M) and OSUR (OraSure Technologies Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $281.4M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANIK?

Per ANIK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000898437), Anika Therapeutics Inc. generated $112.8M in revenue (-5.9% YoY), -$11.0M in net income, and $4.4M in free cash flow against $190.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANIK trading relative to its 50-day, 200-day, and 52-week technical levels?

ANIK last traded at $21.79 (+1.11% on volume of 121,771 shares), positioning the stock +5.47% above its 50-day simple moving average ($20.66) and +35.59% above its 200-day simple moving average ($16.07). Across its 52-week range of $9.01 to $22.88, ANIK sits at the 92.1% percentile with a 14-day RSI of 53.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($20.00 to $23.58).

ANIK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ANIK stock right now?

Anika Therapeutics Inc. (ANIK) currently earns a Roarable Rating of D+ (Sell — SELL) with 55/100 RQD Confidence. Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.

What is ANIK's 12-month price target and RQD AI Jury consensus?

ANIK's 12-month base price target is $21.5 (range $16.77 to $25.37), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ANIK RQD Cockpit ANIK 12M Forecast ANIK Earnings & Move ANIK Dividends & DRIP ANIK Insiders & 13F ANIK Whale Options ANIK Profit Sankey ANIK News & Why